Hematologic Involvement as a Predictor of Mortality in COVID-19 Patients in a Safety Net Hospital.

Autor:	Gonzalez-Mosquera LF; Department of Medicine, Nassau University Medical Center, East Meadow, NY., Gomez-Paz S; Department of Medicine, Division of Gastroenterology, Nassau University Medical Center, East Meadow, NY., Lam E; Department of Medicine, Nassau University Medical Center, East Meadow, NY., Cardenas-Maldonado D; Department of Medicine, Nassau University Medical Center, East Meadow, NY., Fogel J; Department of Business Management, Brooklyn College, Brooklyn, NY., Adi V; Department of Medicine, Nassau University Medical Center, East Meadow, NY., Rubinstein S; Department of Medicine, Division of Nephrology and Hypertension, Nassau University Medical Center, East Meadow, NY.
Jazyk:	angličtina
Zdroj:	Kansas journal of medicine [Kans J Med] 2022 Jan 11; Vol. 15, pp. 8-16. Date of Electronic Publication: 2022 Jan 11 (Print Publication: 2022).
DOI:	10.17161/kjm.vol15.15699
Abstrakt:	Introduction: COVID-19 affects the hematologic system. This article evaluated the impact of hematologic involvement of different blood cell line parameters of white blood cells including absolute neutrophil count (ANC), hemoglobin, and platelets in COVID-19 patients and their association with hospital mortality and length of stay (LOS). Methods: This was a retrospective study of 475 patients with confirmed positive COVID-19 infection and hematologic abnormalities in the metropolitan New York City area. Results: Elevated absolute neutrophil count (OR: 1.20; 95% CI: 1.02-1.42; p < 0.05) increased days of hematologic involvement (OR: 4.44; 95% CI: 1.42-13.90; p < 0.05), and persistence of hematologic involvement at discharge (OR: 2.87; 95% CI: 1.20-6.90; p < 0.05) was associated with higher mortality. Higher hemoglobin at admission (OR: 0.77; 95% CI:0.60-0.98; p < 0.001) and platelets peak (OR: 0.995; 95% CI: 0.992-0.997; p < 0.001) were associated with decreased mortality. Patients with higher white blood cell peak (B = 0.46; SE = 0.07; p < 0.001) and higher hemoglobin at admission (B = 0.05; SE = 0.01; p < 0.001) were associated with higher LOS. Those with higher hemoglobin nadir (B = -0.06; SE = 0.01; p < 0.001), higher platelets nadir (B = -0.001; SE = < 0.001; p < 0.001), and hematologic involvement at discharge or death (B = -0.06; SE = 0.03; p < 0.05) were associated with lower LOS. Conclusions: These findings can be used by clinicians to better risk-stratify patients with hematologic involvement in COVID-19 and tailor therapies potentially to improve patient outcomes. (© 2022 The University of Kansas Medical Center.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu